A round up of studies suggests it is difficult to increase serum total 25-hydroxyvitamin D levels enough to effectively lower elevated parathyroid hormone (PTH) levels in overweight patients with chronic kidney disease.
Intravenous etelcalcetide use remains limited by cost and reimbursement, investigators noted.
Author reviews calciphylaxis incidence, risk factors, pathogenesis, differential diagnoses, and treatment.
A new review highlights the need to simultaneously control CKD-MBD and MICS in patients receiving hemodialysis.
Promising therapies still need to be further evaluated in clinical trials.
Secondary hyperparathyroidism remains uncontrolled in many patients with chronic kidney disease.
Recent studies have shown the importance of starting treatment at lower phosphorus and PTH levels on long-term outcomes of SHPT.
Despite the increasing availability of calcimimetics, parathyroidectomy rates in the US have gradually increased.
Patients at risk for postoperative hypocalcemia need more vigilant postoperative monitoring.
Decrease in bone mass is common in the first 6 to 12 months after kidney transplantation.
